ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Myositis"

  • Abstract Number: 2578 • ACR Convergence 2023

    Machine Learning Identifies New Sporadic Inclusion Body Myositis Endotypes Associated with Unique Autoantibody Profiles

    Jenny Wei1, Mark Tarnopolsky2, Marie Hudson3, Ross Mitchell4, Katherine Buhler5, Antoine Dufour6, Luiz de Almeida6, Paul R. Fortin7, Eric Boilard8, Yann Becker8, Erin Hatcher2, Mei Feng Zhang6, Marvin Fritzler6 and May Choi6, 1University of Toronto, Toronto, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 3McGill University, Montréal, QC, Canada, 4University of Alberta, Edmonton, AB, Canada, 5University of Calgary; Cumming School of Medicine, Calgary, AB, Canada, 6University of Calgary, Calgary, AB, Canada, 7Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, 8Université Laval, Quebec City, QC, Canada

    Background/Purpose: Sporadic inclusion body myositis (sIBM) is a subset of autoimmune inflammatory myopathies (AIM) that is often challenging to diagnose. The objective of this study…
  • Abstract Number: 0287 • ACR Convergence 2023

    6-Minute Walk Distance Associates with Physiologic Measures and Physician/Patient Reported Outcomes in Myositis Related Interstitial Lung Disease

    Sangmee Bae1, Fereidoun Abtin2, Grace Kim3, Daniela Markovic4, Siamak Moghadam-Kia5, Chester V. Oddis6, Lila Pourzand2, Didem Saygin6, Daniel Sullivan7, Koichi Yamaguchi8, Donald Tashkin3, Christina Charles-Schoeman9, Jonathan Goldin3 and Rohit Aggarwal6, 1UCLA Rheumatology, Los Angeles, CA, 2UCLA Radiological Sciences, Los Angeles, CA, 3University of California Los Angeles, Los Angeles, CA, 4UCLA Department of Medicine Statistics Core, Los Angeles, CA, 5University of Pittsburgh Medical Center, Pittsburgh, PA, 6University of Pittsburgh, Pittsburgh, PA, 7UCLA Pulmonology, Pittsburgh, PA, 8University of Pittsburgh Medical Center Rheumatology, Pittsburgh, PA, 9UCLA Medical Center, Santa Monica, CA

    Background/Purpose: The 6 minute walk distance (6MWD) provides a global evaluation of sub-maximal exercise capacity that is easily performed and highly reproducible, and is used…
  • Abstract Number: 0664 • ACR Convergence 2023

    Quantitative Hand Held Dynamometry to Assess Muscle Strength in Scleroderma Associated Myopathy

    Julie Paik1, Christopher Mecoli2, Anshula Nallapati1, Ami Shah3, Fred Wigley4, Zsuzsanna McMahan5 and Laura Hummers1, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, 4Department of Rheumatology, Johns Hopkins Medicine, Baltimore, MD, 5Johns Hopkins Rheumatology, Lutherville, MD

    Background/Purpose: Manual muscle strength testing can be challenging in SSc associated myopathy (SSc-AM) due to contractures or skin tightening. Since there is currently no validated…
  • Abstract Number: 1169 • ACR Convergence 2023

    All-cause Mortality and Risk Factors for Death in a Large Multi-center Prospective Registry Cohort of Idiopathic Inflammatory Myositis in China

    Liying Peng1, Peng Yin2, Mucong Li3, Qian Wang4, Yanhong wang1, Shuang Zhou4, chanyuan wu4, Jiuliang zhao1, Dong xu5, Mengtao Li3 and xiaofeng Zeng4, 1Peking Union Medical College, Beijing, China, 2Chinese Center for Disease Control and Prevention, Beijing, China, 3Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 4Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 5Peking Union Medical College Hospital, Beijing, China

    Background/Purpose: Our study depicted the mortality and independent risk factors of IIM patients in a large multi-center prospective registry cohort in China. Methods: Patients registered…
  • Abstract Number: 1927 • ACR Convergence 2023

    Manifestations, Management and Outcomes of Interstitial Lung Disease Associated with Anti-synthetase Syndrome: A Systematic Literature Review

    Koushan Kouranloo1, Mrinalini Dey2, Veronica Yioe3, Lisa G Spencer3 and Caroline V Cotton4, 1Rheumatology & Internal Medicine Trainee- Surrey, UK. Education fellow University of Liverpool, Liverpool, United Kingdom, 2Queen Elizabeth Hospital, London, United Kingdom; University of Liverpool, Liverpool, United Kingdom, 3Liverpool Regional Lung Disease Service, Aintree Hospital, Lower Lane, Liverpool, United Kingdom, 4Department of rheumatology, Liverpool University NHS Foundation Trust, Liverpool, United Kingdom

    Background/Purpose: Anti-synthetase syndrome (ASS) is a chronic autoimmune inflammatory condition, characterized by myositis, interstitial lung disease (ILD), arthritis, Raynaud's phenomenon and mechanic's hands. This systematic…
  • Abstract Number: 1965 • ACR Convergence 2023

    Discordance Between Patient and Physician Perception of Disease Activity Among Patients with Idiopathic Inflammatory Myopathies: Results from the COVAD Study

    Mrinalini Dey1, Rudra Prosad Goswami2, Parikshit Sen3, Samuel Shinjo4, Nelly Ziade5, Ioannis Parodis6, Mrudula Joshi7, Marcin Milchert8, Abraham Edgar Gracia-Ramos9, Lorenzo Cavagna10, Vishwesh Agarwal11, Johannes Knitza12, Jessica Day13, Hector Chinoy14, COVAD Study Group15, Vikas Agarwal16, Rohit Aggarwal17 and Latika Gupta18, 1Queen Elizabeth Hospital, London, United Kingdom; University of Liverpool, Liverpool, United Kingdom, 2Department of Rheumatology, All India Institute of Medical Sciences, New Delhi, India, 3Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, Delhi-110002, India., Dalhi, India, 4Faculdade de Medicina FMUSP, Universidade de Sao Paulo, São Paulo, Brazil, 5Saint-Joseph University, Beirut, Lebanon, 6Karolinska Institutet, Stockholm, Sweden, 7Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, 8Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland, 9Department of Internal Medicine, General Hospital, National Medical Center "La Raza", Instituto Mexicano del Seguro Social, Av. Jacaranda S/N, Col. La Raza, Del. Azcapotzalco, C.P. 02990, Mexico City, Mexico, 10Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, 11Mahatma Gandhi Missions Medical College, Lucknow, India, 12Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, 13Walter and Eliza Hall Institute, Melbourne, Australia, 14The University of Manchester, Sale, United Kingdom, 15-, -, 16Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, 17University of Pittsburgh, Pittsburgh, PA, 18Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom

    Background/Purpose: Disease activity assessment is key in the management of patients with idiopathic inflammatory myopathies (IIM). However, patients' perception of disease may differ from clinicians.…
  • Abstract Number: 2579 • ACR Convergence 2023

    Validation of PROMIS in Adult and Pediatric Patients with Idiopathic Inflammatory Myopathies

    Emma Austenfeld1, Sara Sabbagh1, Melodee Liegl1, Ke Yan1, Julie Fuller2, Kelly Rouster-Stevens3, Lisa Rider4 and Adam Schiffenbauer4, 1Medical College of Wisconsin, Wauwatosa, WI, 2UT Southwestern and Scottish Rite for Children, Dallas, TX, 3Emory University/Children's Healthcare of Atlanta, Norcross, GA, 4NIEHS, NIH, Bethesda, MD

    Background/Purpose: This study aimed to validate the Patient Reported Outcome Measurement Information System (PROMIS) tools in patients with adult and juvenile idiopathic inflammatory myopathies (IIM/JIIM)…
  • Abstract Number: 028 • 2023 Pediatric Rheumatology Symposium

    Achieving Medication-Free Remission in Juvenile Dermatomyositis

    Harneet Ghumman1, Ilaria Maccora2, Hermine Brunner1, Amy Cassedy3, Mekibib Altaye2, Asra Firdous1, Alexei Grom1, Daniel Lovell1, Angela Merritt1, Megan Quinlan-Waters1 and Sheila Angeles-Han2, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cincinnati Children's Hospital, Cincinnati, OH, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Juvenile dermatomyositis (JDM) is characterized by symmetric proximal muscle weakness, distinct rash, and a risk for calcinosis. Systemic immunosuppression is needed. Evidence is limited…
  • Abstract Number: 064 • 2023 Pediatric Rheumatology Symposium

    Towards the Development of Composite Parent-Centered Disease Activity Scores for Juvenile Dermatomyositis

    Silvia Rosina1, Ana Isabel Rebollo-Giménez2, Letizia Tarantola3, Roberta Naddei4, Alessandro Consolaro2, Angela Pistorio5 and Angelo Ravelli6, 1IRCCS Istituto Giannina Gaslini, Genova, Italy, 2IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Infiammatorie, Genova, Italy, 3Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genova, Italy, 4Università degli Studi di Napoli Federico II, Dipartimento di Scienze Mediche Traslazionali, Napoli, Italy, 5IRCCS Istituto Giannina Gaslini, Direzione Scientifica, Genova, Italy, 6IRRCS Istituto Giannina Gaslini and Università degli Studi di Genova, Genova, Italy

    Background/Purpose: Increasing attention has been recently paid to the development of parent- and child-centered composite DAS for the assessment of health status of children with…
  • Abstract Number: 100 • 2023 Pediatric Rheumatology Symposium

    The Brazilian Registry of Juvenile Dermatomyositis (JDM): II – A Longitudinal Assessment of Muscle Strength by Manual Muscle Test (MMT) and Childhood Myositis Assessment Scale (CMAS) Tools

    Darcisio Antonio1, Taciana Fernandes1, Adriana Elias2, Teresa Robazzi3, Ana Julia Moraes4, Sheila Oliveira5, Flavio Sztajnbok6, Luciana Carvalho7, Luciana Marques8, Silvana Sacchetti9, Maria Teresa Terreri10, Simone Appenzelle11, Roberto Marini12, Carlos Rabello Jr13, Cristina Magalhaes14, Melissa Fraga15, Marcia Bandeira16, Iloite Scheibel17, Isabela Daud2, Beatriz Carneiro2, Claudio Len18, Clovis Silva19 and Claudia Magalhaes20, 1Universidade Estadual Paulista (UNESP) Botucatu, Brazil, 2Instituto da Criança - Universidade de São Paulo (USP), São Paulo, Brazil, 3Universidade Federal da Bahia, Brazil, 4Universidade Federal do Para, Brazil, 5Universidade Federal do Rio de janeiro, Rio de Janeiro, 6Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Brazil, 7Universidade de Sao Paulo- Ribeirao Preto, São Paulo, Brazil, 8Hospital Albert Sabin, Brazil, 9Santa Casa de Sao Paulo, Brazil, 10UNIFESP, São Paulo, Brazil, 11University of Campinas, Campinas, Sao Paulo, Brazil, 12UNICAMP, São Paulo, Brazil, 13Hospital Geral de Fortaleza, Brazil, 14Hospital Jose de Alencar - Brasilia, Brazil, 15Hospital Darcy Vargas, Brazil, 16Hospital Pequeno Principe- Curitiba, Brazil, 17Hospital Conceição de Porto Alegre, Brazil, 18Universidade Federal de São Paulo - Unifesp, São Paulo, Brazil, 19Universidade de São Paulo, São Paulo, Brazil, 20São Paulo State University, Pediatric Rheumatology Division, Botucatu, Brazil

    Background/Purpose: Muscle weakness is often progressive and persistent in Juvenile Dermatomyositis (JDM). Muscle strength testing is useful for evaluating severity of muscle weakness. There is…
  • Abstract Number: 120 • 2023 Pediatric Rheumatology Symposium

    The Brazilian Registry of Juvenile Dermatomyositis (JDM): I- Onset Clinical Features and Disease Activity Scores by DAS-20 over 2-Years-Follow Up

    Beatriz Carneiro1, Adriana Elias1, Teresa Robazzi2, Ana Julia Moraes3, Sheila Oliveira4, Flavio Sztajnbok5, Luciana Carvalho6, Luciana Marques7, Silvana Sacchetti8, Maria Teresa Terreri9, Simone Appenzelle10, Roberto Marini11, Andre Cavalcante12, Marcia Bandeira13, Cristina Magalhaes14, Melissa Fraga15, Iloite Scheibel16, Isabela Daud1, Darcisio Antonio17, Claudio Len18, Clovis Silva19, Taciana Fernandes17 and Claudia Magalhaes20, 1Instituto da Criança - Universidade de São Paulo (USP), São Paulo, Brazil, 2Universidade Federal da Bahia, Brazil, 3Universidade Federal do Para, Brazil, 4Universidade Federal do Rio de janeiro, Rio de Janeiro, 5Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Brazil, 6Universidade de Sao Paulo- Ribeirao Preto, São Paulo, Brazil, 7Hospital Albert Sabin, Brazil, 8Santa Casa de Sao Paulo, Brazil, 9UNIFESP, São Paulo, Brazil, 10University of Campinas, Campinas, Sao Paulo, Brazil, 11UNICAMP, São Paulo, Brazil, 12Hospital Materno-Infantil de Goiania, Brazil, 13Hospital Pequeno Principe- Curitiba, Brazil, 14Hospital Jose de Alencar - Brasilia, Brazil, 15Hospital Darcy Vargas, Brazil, 16Hospital Conceição de Porto Alegre, Brazil, 17Universidade Estadual Paulista (UNESP) Botucatu, Brazil, 18Universidade Federal de São Paulo - Unifesp, São Paulo, Brazil, 19Universidade de São Paulo, São Paulo, Brazil, 20São Paulo State University, Pediatric Rheumatology Division, Botucatu, Brazil

    Background/Purpose: A national registry was set up, enrolling new onset JDM cases in 18 hospitals, during 3-years (2015-2018) with 2-years follow up, in a low…
  • Abstract Number: L10 • ACR Convergence 2022

    Efgartigimod Prevents Necrosis and Allows for Muscle Fiber Regeneration in a Humanized Mouse Model of Immune-mediated Necrotizing Myopathy (IMNM)

    Sarah Julien1, Emma Briand1, Bas van der Woning2, Leentje de ceuninck3, Rachid zoubari1, olivier benveniste4, laurent drouot1 and olivier boyer5, 1INSERM U1234, PAn’THER FOCIS Center of Excellence, Rouen, France, 2argenx, Boston, MA, 3argenx, Ghent, Belgium, 4AP-HP, Pitié-Salpêtrière University Hospital, Department of Internal Medicine and Clinical Immunology, Paris, France, 5INSERM U1234, PAn’THER FOCIS Center of Excellence; Rouen University Hospital, Department of Immunology and Biotherapy, Rouen, France

    Background/Purpose: Immune-mediated necrotizing myopathy (IMNM) is a severe form of myositis characterized by muscle weakness and elevated creatine kinase levels in serum. The most frequent…
  • Abstract Number: 0155 • ACR Convergence 2022

    Validity of the Mawdsley Calcinosis Questionnaire in Adult and Juvenile Dermatomyositis (DM, JDM) Patients with Calcinosis

    Sarvar Nazir1, Kelly Rouster-Stevens2, Julie Fuller3, Hanna Kim4, Vy Do5, Rita Volochayev6, Anna Jansen6, Nastaran Bayat7, Lisa G Rider8 and Adam Schiffenbauer6, 1National Institutes of Health, Charlotte, NC, 2Emory University/Children's Healthcare of Atlanta, Atlanta, GA, 3UT Southwestern, Frisco, TX, 4Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, 5UT Austin Dell Medical School, Austin, TX, 6National Institutes of Health, Bethesda, MD, 7Social & Scientific Systems, Inc., a DLH Holdings Corp (DLH) company, Bethesda, MD, 8Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD

    Background/Purpose: Calcinosis is a complication of the idiopathic inflammatory myopathies (IIM) in which calcium salts are deposited in and around soft tissue, which can impact…
  • Abstract Number: 0178 • ACR Convergence 2022

    Muscle Fibres Play a Critical Role in Therapeutic Response of Myositis to Glucocorticoids Through Polarisation of the Inflammatory Infiltrate by a Paracrine Mechanism

    Margherita Giannini1, Daniela Rovito2, Léa Debrut3, Céline Keime4, Beatrice Lannes5, Anne-Laure Charles3, Delphine Duteil2, Bernard Geny6, Daniel Metzger2, Gilles Laverny2 and Alain Meyer1, 1Service de Physiologie et explorations fonctionnelles, CHU, Strasbourg ; Centre de Référence des Maladies Autoimmunes Rares, CHU, Strasbourg ; UR3072, Centre de Recherche en Biomédecine, University of Strasbourg, Strasbourg, France, 2University of Strasbourg, CNRS UMR7104, INSERM U1258, IGBMC, F-67400, Illkirch, France, 3UR3072 Centre de Recherche en Biomédecine, University of Strasbourg, Strasbourg, France, 4University of Strasbourg, CNRS UMR 7104, INSERM UMR-S 1258, IGBMC, F-67400, Illkirch, France, 5Département de pathologie, Centre de référence des maladies neuromusculaires, CHU Strasbourg, University of Strasbourg, Strasbourg, France, 6Service de Physiologie et explorations fonctionnelles, CHU, Strasbourg ; UR3072 Centre de Recherche en Biomédecine, University of Strasbourg, Strasbourg, France

    Background/Purpose: Glucocorticoids (GC) are the first line treatment for myositis patients. They improve muscle strength, yet muscle recovery is generally partial and long lasting treatment…
  • Abstract Number: 1864 • ACR Convergence 2022

    Hepatitis B Exposure and Infection in Idiopathic Inflammatory Myopathies: Prevalence, Presentation, and Treatment Response

    Ana Valle1, Xianhong Xie2 and Shereen Mahmood3, 1Montefiore Medical Center, New York, NY, 2Department of Epidemiology & Population Health/Albert Einstein College of Medicine, Bronx, NY, 3Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY

    Background/Purpose: Hepatitis B (HBV) screening in patients with autoimmune conditions is vital prior to the initiation of immunosuppressive therapy given the risk of HBV reactivation.…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 28
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology